Your browser is no longer supported. Please, upgrade your browser.
Xeris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own2.30% Shs Outstand46.15M Perf Week-6.12%
Market Cap266.73M Forward P/E- EPS next Y-1.36 Insider Trans-0.87% Shs Float44.09M Perf Month13.05%
Income-102.40M PEG- EPS next Q-0.39 Inst Own54.30% Short Float11.97% Perf Quarter1.32%
Sales15.10M P/S17.66 EPS this Y-66.60% Inst Trans0.05% Short Ratio3.10 Perf Half Y87.11%
Book/sh0.31 P/B17.32 EPS next Y37.90% ROA-72.90% Target Price- Perf Year-14.29%
Cash/sh2.85 P/C1.88 EPS next 5Y- ROE-510.40% 52W Range1.42 - 7.16 Perf YTD9.15%
Dividend- P/FCF- EPS past 5Y- ROI-167.70% 52W High-25.00% Beta-
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin50.40% 52W Low278.17% ATR0.41
Employees172 Current Ratio6.00 Sales Q/Q2918.50% Oper. Margin- RSI (14)52.37 Volatility7.50% 8.33%
OptionableYes Debt/Eq0.00 EPS Q/Q71.60% Profit Margin- Rel Volume1.33 Prev Close5.74
ShortableYes LT Debt/Eq8.35 EarningsNov 09 BMO Payout- Avg Volume1.70M Price5.37
Recom1.60 SMA201.04% SMA508.96% SMA20027.00% Volume2,271,614 Change-6.45%
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
Jan-15-21 08:25AM  
Jan-07-21 01:00PM  
Jan-05-21 04:05PM  
Dec-31-20 04:05PM  
Dec-29-20 08:58AM  
Dec-22-20 07:00AM  
Dec-16-20 09:53AM  
Dec-13-20 10:34PM  
Dec-11-20 04:00AM  
Nov-27-20 01:05PM  
Nov-12-20 08:17AM  
Nov-09-20 01:30PM  
Nov-02-20 07:00AM  
Oct-30-20 04:05PM  
Oct-29-20 12:34PM  
Oct-28-20 02:41PM  
Oct-21-20 08:04AM  
Oct-20-20 04:05PM  
Oct-19-20 01:41PM  
Oct-12-20 08:21PM  
Oct-02-20 04:05PM  
Sep-22-20 03:52PM  
Sep-08-20 08:00AM  
Aug-28-20 04:05PM  
Aug-26-20 10:35AM  
Aug-21-20 07:43AM  
Aug-20-20 04:15PM  
Aug-18-20 08:57AM  
Aug-11-20 08:49AM  
Aug-10-20 04:00PM  
Aug-03-20 04:05PM  
Jul-31-20 04:05PM  
Jul-30-20 08:00AM  
Jul-28-20 12:33PM  
Jul-15-20 04:05PM  
Jul-12-20 05:56AM  
Jul-06-20 08:02AM  
Jul-01-20 07:00AM  
Jun-30-20 08:03PM  
Jun-26-20 04:05PM  
Jun-25-20 09:32PM  
Jun-24-20 04:01PM  
Jun-18-20 08:00AM  
Jun-15-20 09:19AM  
May-29-20 04:05PM  
May-26-20 10:11AM  
May-22-20 08:00AM  
May-14-20 02:14PM  
May-09-20 05:02PM  
May-07-20 10:35AM  
Apr-30-20 08:00AM  
Apr-29-20 07:00AM  
Apr-28-20 06:43AM  
Apr-20-20 08:00AM  
Mar-27-20 05:30PM  
Mar-26-20 04:15PM  
Mar-19-20 08:00AM  
Mar-16-20 08:10AM  
Mar-11-20 07:30AM  
Mar-04-20 12:30PM  
Feb-28-20 04:05PM  
Feb-27-20 04:05PM  
Feb-20-20 04:05PM  
Feb-18-20 09:00AM  
Feb-12-20 09:18AM  
Feb-11-20 07:07PM  
Feb-10-20 04:06PM  
Jan-31-20 04:05PM  
Jan-07-20 07:57AM  
Jan-06-20 05:01PM  
Dec-29-19 09:40PM  
Dec-27-19 04:05PM  
Dec-22-19 05:09PM  
Dec-11-19 07:21AM  
Dec-10-19 05:33PM  
Dec-02-19 06:37AM  
Nov-29-19 01:05PM  
Nov-21-19 06:00AM  
Nov-07-19 03:09PM  
Nov-01-19 04:05PM  
Oct-30-19 10:33AM  
Oct-25-19 02:22PM  
Oct-01-19 08:00AM  
Sep-27-19 04:05PM  
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRESTRELSKI STEVENChief Scientific OfficerJan 13Sale6.0110,00060,058406,824Jan 15 04:03 PM
PRESTRELSKI STEVENChief Scientific OfficerJan 11Sale5.7210,00057,244416,824Jan 12 04:02 PM
Edick Paul RSee RemarksDec 09Buy4.0610,00040,551411,134Dec 10 04:52 PM
Shannon John Patrick JrSee RemarksMay 13Buy3.5522,00077,994117,493May 14 04:30 PM
Shannon John Patrick JrSee RemarksMay 08Buy3.207,88625,21995,493May 11 06:17 PM
Edick Paul RSee RemarksMay 08Buy3.0033,00099,000401,134May 11 05:06 PM
Hecht BethSee RemarksMar 13Buy1.974,0007,88057,083Mar 16 04:07 PM
Hecht BethSee RemarksFeb 14Buy4.154,00016,6008,083Feb 18 05:02 PM
Shannon John Patrick JrSee RemarksFeb 14Buy4.1512,04849,99922,607Feb 18 05:02 PM
Edick Paul RSee RemarksFeb 14Buy4.1520,00083,000183,134Feb 18 05:02 PM
JOHNSON KENNETH ERLANDSee RemarksFeb 14Buy4.152,41010,0026,115Feb 18 04:59 PM
Deutsch Barry M.See RemarksFeb 14Buy4.159,63940,00239,359Feb 18 04:55 PM